Prebiotic Gut Microbiome Randomized Trial: What the Evidence Says

Quick Answer

Prebiotic Gut Microbiome Randomized Trial has 3 source documents in the current Migaku evidence database. The strongest available sources in this first pass are randomized trial, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 1 randomized trial, 1 narrative review, 1 research article.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• Consequently, previous research has found bowel management to be a top priority among individuals with SCI. [Trunz Julia (2026); evidence level 2]
• Disruption of neural pathways and autonomic imbalance after the onset of SCI can lead to impaired colonic motility, delayed colonic transit time, and increased barrier permeability in the intestine. [Trunz Julia (2026); evidence level 2]
• There is strong evidence of a correlation linking gut dysbiosis with reduced microbial diversity and a disruption in the balance of microbial communities, and inflammatory and metabolic disorders, including obesity and type 2 diabetes mellitus (T2DM). [Alhaj Omar A. (2026); evidence level 3]
• Meta-analyses of clinical interventions corroborate the results of regular yogurt or kefir intake, showing significant decreases in fasting glucose, low-density lipoprotein (LDL) cholesterol, and systemic C-reactive protein (CRP) in dysbiosis-associated conditions, with effect sizes dependent on strain composition, dose, and host genotype. [Alhaj Omar A. (2026); evidence level 3]
• Similarly, the-diversity of dbCAN3 PUL prediction increased at month 3 in the prebiotic group (0 vs.3  0.005,, upper, Table S2), while the placebo group showed a decline after month 3 (0 vs.6 = 0.024;3 vs.6 = 0.055,, upper, Table S2). [Wang Weilan (2026); evidence level 4]
• Phenotype-microbiome revealed that, of the 163 species significantly associated with hand grip strength, 99 were also significantly associated with lean mass, while only 22 overlapped with trunk fat percentage (&#8201;<&#8201;0.05, Fig. [Wang Weilan (2026); evidence level 4]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

There is trial evidence in the current set, but population and intervention details still matter. For prebiotic gut microbiome randomized trial, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Trunz Julia (2026). Probiotic and Prebiotic Supplementation for Gastrointestinal Discomfort in Chronic Spinal Cord Injury (PRO-GIDSCI): A Randomized Controlled Crossover Trial Protocol. DOI: 10.3390/mps9010014. PMCID: PMC12821591. PMID: 41562992. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC12821591/
• Alhaj Omar A. (2026). Dairy Bioactive Compounds as Precision Modulators of Gut Microbiota: From Molecular Mechanisms to Personalized Immunometabolic Health. DOI: 10.3390/foods15112024. PMCID: PMC13256291. PMID: 42279810. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13256291/
• Wang Weilan (2026). Multiomics insights into the effects of prebiotics on physical function and metabolism in adults with obesity and knee osteoarthritis. DOI: 10.1080/19490976.2026.2679516. PMCID: PMC13240952. PMID: 42231528. License: https://creativecommons.org/licenses/by-nc/4.0/ http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access.... https://pmc.ncbi.nlm.nih.gov/articles/PMC13240952/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.